SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Social media discourse surrounding SpaceX is currently dominated by warnings about illegitimate crypto tokens impersonating the company ahead of a rumored future IPO. While some users express genuine interest in tracking the company's valuation through related space sector ETFs and proxies, the community is heavily focused on labeling these tokenized 'pre-stocks' as potential scams and rug pulls.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is generating significant buzz as investors weigh the company's aggressive AI and cloud infrastructure pivot against upcoming earnings and high-stakes geopolitical trade talks. While the community is split between bullish sentiment over long-term AI potential and skepticism surrounding recent earnings volatility, attention is heavily focused on whether institutional positioning will trigger a re-rating for the stock.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is trending as the community highlights its AI-native infrastructure, with recent activity fueled by platform developments and rumors of a potential buyout. Investors are actively discussing the token's long-term utility in the Base ecosystem and debating whether current market price action offers an accumulation opportunity or signs of manipulation.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies is drawing significant investor interest due to its pivot toward a vertically integrated U.S. supply chain for critical minerals and rare earth magnets, which community members view as a strategic hedge against international trade tensions. While some participants are wary of potential volatility and bot activity, the stock is currently trending on the back of news regarding infrastructure expansion and institutional investment, fueling speculation about its long-term role in domestic industrial independence.

Lowe's Companies, Inc. engages in the retail sale of home improvement products. The firm offers products for maintenance, repair, remodeling, home decorating, and property maintenance. It also provides home improvement products in the following categories: appliances, seasonal & outdoor living, lumber, lawn & garden, kitchens & bath, hardware, building materials, millwork, paint, rough plumbing, tools, electrical, flooring, and décor. The company was founded in 1946 and is headquartered in Mooresville, NC.

Lowe`s Cos., Inc.

Lowe's Companies, Inc.

Lowe's Companies, Inc. is trending as investors digest a mix of analyst upgrades and downgrades while monitoring the stock's performance ahead of its upcoming earnings report. The community remains focused on how the home improvement sector, particularly Lowe's and Home Depot, will navigate broader macroeconomic headwinds and fluctuating interest rates.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A. Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is currently trending due to the completed enrollment of its Phase 3 SENTRY trial for myelofibrosis, though community discussion remains deeply polarized by frustration over persistent financial instability and long-standing concerns regarding executive leadership. Investors are actively debating the potential for a clinical turnaround against the backdrop of an extended cash runway and the company's challenging historical performance.

Harvest Portfolios Group Inc - Harvest Canadian High Income Shares ETF

Harvest Canadian High Income Shares ETF

Investors are closely monitoring the ETF's performance in light of news regarding its underlying major holdings and are actively discussing the benefits of dividend compounding through monthly distributions. The community is focused on the fund's resilience during broader market fluctuations, often weighing its strategy of maintaining exposure to leading Canadian companies.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is currently trending as investors focus on its RNA-based pipeline and the potential for strategic M&A following GSK's decision to return rights for its AATD candidate. The community is actively discussing the stock's long-term potential in the obesity market, with significant attention on upcoming trial data readouts and how the company's muscle-sparing approach compares to current GLP-1 standards.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

UniSwap is generating intense community discussion due to the 'UNIfication' governance proposal, which focuses on activating a fee switch to reward token holders and initiating a massive token burn to reduce supply. Traders are closely monitoring these potential tokenomic shifts, viewing them as a critical catalyst for long-term sustainability and value appreciation.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is seeing significant community interest driven by its strategic acquisition of Covelya Group, which bolsters its subsea technology platform, and heightened geopolitical focus on critical underwater infrastructure protection. Investors are actively discussing the company's long-term defense sector role, its potential for major exchange uplisting, and strong revenue growth outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biomea Fusion Status Update: Experts Discuss Icovamenib's Promise Ahead of ADA 2026

Rodman & Renshaw Director of Research Michael King hosted an endocrinology-focused discussion with Dr. Alexander Abitbol, an endocrinologist and assistant medical director at LMC Healthcare, ahead of the American Diabetes Association (ADA) meeting in New Orleans. The conversation centered on tre...

Biomea Fusion (NASDAQ:BMEA) Coverage Initiated by Analysts at Citizens Jmp

Citizens Jmp began coverage on shares of Biomea Fusion in a research note on Tuesday. They issued a 'market outperform' rating and a $9.00 target price on the stock...

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of "Moderate Buy" from Analysts

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings...

Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib

Biomea Fusion (NASDAQ:BMEA) executives highlighted early, exploratory clinical data for icovamenib in type 1 diabetes, presenting top-line results from the company's COVALENT-112 proof-of-concept...

Biomea Fusion (NASDAQ:BMEA) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued a "buy" rating and issued a $12.00 price objective on shares of Biomea Fusion in a research report on Tuesday...

Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Monday

Biomea Fusion (NASDAQ:BMEA) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-4-biomea-fusion-inc-stock...

Biomea Fusion (NASDAQ:BMEA) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated a "buy" rating and issued a $12.00 price objective on shares of Biomea Fusion in a research note on Wednesday...

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine ratings firms that are covering the company, Marketbeat reports. One investment...

Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts

Executives from Biomea Fusion (NASDAQ:BMEA) discussed the company's lead diabetes program, icovamenib, and outlined near-term clinical milestones during a recent company event hosted by an operator...

Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes

Biomea Fusion (NASDAQ:BMEA) outlined several near-term clinical milestones and development priorities during a JPMorgan conference call, with executives emphasizing upcoming Phase I data for its oral GLP-1 receptor agonist candidate BMF-650 and continued advancement of icovamenib in diabetes.

BMF-6...

This account has been verified as an official BMEA representative.

Verified Account

Biomea Fusion IR

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.

Current Price	$1.35
Prev Close	$1.43
Open	$1.42
Dividend Yield	0.00%
50-Day Moving Average	$1.55
Beta	1.57
Avg. Volume	1.97M
PE Ratio	-1.51

52-Week High	$3.08
52-Week Low	$0.8719
Market Capitalization	$97.6M
EPS (Annual)	-$1.18
Price to Book	5.21
Revenue Per Employee	$0.00

BMEA
Biomea Fusion Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BMEA News

BMEABiomea Fusion Inc